

1 *This is the peer reviewed version of the following article: Melguizo-Rodríguez L., Manzano-*
2 *Moreno F.J., De Luna-Bertos E., Rivas A., Ramos-Torrecillas J., Ruiz C., García-Martínez O.*
3 *Effect of olive oil phenolic compounds on osteoblast differentiation. European Journal of*
4 *Clinical Investigation, 2018; 48(4): 1-6, which has been published in final form at*
5 *10.1111/eci.12904. This article may be used for non-commercial purposes in accordance with*
6 *Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be*
7 *enhanced, enriched or otherwise transformed into a derivative work, without express*
8 *permission from Wiley or by statutory rights under applicable legislation. Copyright notices*
9 *must not be removed, obscured or modified. The article must be linked to Wiley's version of*
10 *record on Wiley Online Library and any embedding, framing or otherwise making available*
11 *the article or pages thereof by third parties from platforms, services and websites other than*
12 *Wiley Online Library must be prohibited.*

13

14 **Effect of olive oil phenolic compounds on osteoblast differentiation**

15 **Melguizo-Rodríguez Lucia, MSc^{a,b}, Manzano-Moreno Francisco Javier, PhD^{a,b,c}, De**
16 **Luna-Bertos Elvira, PhD^{a,b}, Rivas Ana, PhD^{b,d}, Ramos-Torrecillas Javier, PhD^{a,b}, Ruiz**
17 **Concepción, Prof^{a,b,e}, García-Martínez Olga, PhD^{a,b}.**

- 18 a. Biomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences.
19 University of Granada (Spain). Avda. De la Ilustración 60, 18016, Granada, Spain.
- 20 b. Instituto Investigación Biosanitaria, ibs.Granada. C/ Dr. Azpitarte 4 - 4^a planta. 18012
21 Granada. Spain
- 22 c. Department of Stomatology, School of Dentistry, University of Granada. Campus de
23 Cartuja s/n, 18071, Granada, Spain
- 24 d. AGR-255 Group. Department of Nutrition and Food Sciences, Faculty of Pharmacy,
25 University of Granada. Campus de Cartuja s/n, 18071. Granada, Spain.
- 26 e. Institute of Neuroscience Federico Olóriz, University of Granada. Avda. del
27 Conocimiento S/N. 18016. Armilla (Granada), Spain.

28 **Corresponding author:**

29 Dr. Javier Ramos Torrecillas

30 E-mail: jrt@ugr.es

1 **Address:** Department of Nursing, Faculty of Health Sciences. University of Granada. Avda.
2 De la Ilustración 60, 18016, Granada, Spain. Tel. +34 958 24 28 74; Fax +34 958 24 28 94

3 **Address to which requests for reprints should be sent:** Department of Nursing, Faculty of
4 Health Sciences. University of Granada. Avda. De la Ilustración 60, 18016, Granada, Spain.

5 **ABSTRACT**

6 **Background:** Osteoporosis is a skeletal disorder characterized by compromised bone strength
7 that predisposes individuals to an increased risk of fracture. Previous *in vivo* and *in vitro*
8 studies have reported that phenolic compounds present in extra virgin olive oil have a
9 beneficial effect on osteoblasts in terms of increase cell proliferation. The aim of this study
10 was to determine whether phenolic compounds present in olive oil could modify the
11 expression of cell differentiation markers on osteoblasts.

12 **Study Design:** An *in vitro* experimental design was performed using MG-63 osteoblasts cell
13 line.

14 **Methods:** MG63 cells were exposed to different doses of luteolin, apigenin, or p-coumaric,
15 caffeic, or ferulic acid. Alkaline phosphatase (ALP) was evaluated by spectrophotometry and
16 antigen expression (CD54, CD80, CD86, and HLA-DR) by flow cytometry.

17 **Results:** At 24 h, treated groups showed an increased ALP and modulated antigen profile,
18 with respect to the non-treated group.

19 **Conclusion:** These results demonstrate that the phenolic compounds studied induce cell
20 maturation *in vitro*, increasing ALP synthesis and reducing the expression of antigens
21 involved in immune functions of the osteoblast which would improve bone density.

22

1 **Keywords:** phenolic compounds, *olea europaea*, osteoblastic cells, phenotype profile,
2 alkaline phosphatase activity.

3 **Abbreviations:** ALP, Alkaline phosphatase; CD54, Cluster of Differentiation 54; CD80,
4 Cluster of Differentiation 80; CD86, Cluster of Differentiation 86, HLA-DR, Human
5 Leucocyte Antigen D-Related, DMEM, Dulbecco's Modified Eagle Medium; HEPES, 4-(2-
6 hydroxyethyl)-1-piperazineethanesulfonic acid; FBS, fetal bovine serum; EDTA, ethylene
7 diamine tetra-acetic acid; PBS, phosphate-buffered saline; mAb, monoclonal antibody; FITC,
8 Fluorescein-Isothiocyanate; TGF- β 1, Transforming Growth Factor beta 1, IL1 β , Interleukin-1
9 beta; IFN γ , Interferon gamma; LPS, Lipopolysaccharide, IL-4,12,15,18, Interleukin
10 4,12,15,18; FGF, Fibroblast Growth Factor; PDGF, Platelet-Derived Growth Factor; DCs,
11 Dendritic cells.

12

13

14

15

16

17

18

19

20

1. INTRODUCTION

Bone metabolic diseases develop when there is an imbalance between the formation and resorption of bone, that depend on the interaction between osteoblasts and osteoclasts. Osteoporosis is the most common bone metabolic disease in adults, especially among the elderly, which is characterized by compromised bone strength that predisposes individuals to an increased risk of fracture. Most current pharmacological approaches focus on inhibiting bone resorption in patients with osteoporosis or at risk of developing the disease [1,2]. However, researchers have also provided evidence on dietary components that can optimize bone mass and stimulate bone formation [3]. Thus, Habauzit & Horcajada (2008) reported that phytonutrients in our diet, especially polyphenols, can act on both osteoblasts and osteoclasts to modulate bone metabolism.

Bone formation involves a complex series of events, including osteoprogenitor cell proliferation and differentiation, which eventually result in the formation of a mineralized extracellular matrix. Numerous cytokines, hormones, and growth factors control bone formation by regulating osteoblast cell proliferation and differentiation [5]. Bone is a dynamic tissue under continuous remodeling process where osteoblasts, which derive from undifferentiated pluripotent mesenchymal cells [6], are responsible for bone development. It has been described that osteoblasts have immunological functions because the expression of markers of antigen-presenting capacity (CD54, CD80, CD86, HLA-DR) which is modulated in the presence of cytokines, growth factors, platelet-rich plasma, bacterial lipopolysaccharide, or even certain pharmaceuticals [7–12].

Olive oil is the main fat used in the Mediterranean Diet and contains numerous minor compounds, including phenolic compounds, that can be divided among phenolic acids, phenolic alcohols, secoiridoids, lignans, and flavones [13–15].

1 It has been demonstrated that phenolic compounds can modulate osteoblast cell functions [16–
2 20]. However, to our knowledge, no data are available on the ability of olive oil phenolic
3 compounds to regulate cultured osteoblast differentiation. The objective of the present study
4 was to determine the effect of phenolic compounds on osteoblastic (MG-63) cell differentiation
5 by evaluating the antigenic profile and alkaline phosphatase (ALP) activities.

6

7 **2. MATERIAL AND METHODS**

8 **2.1. Study Design**

9 An *in vitro* experimental design was performed using MG-63 osteoblasts cell line.

10 **2.2. Chemicals compounds**

11 Standards of apigenin, luteolin and caffeic, p-coumaric, and ferulic acids were purchased from
12 Sigma-Aldrich (St. Louis, MO). Stock solutions of phenolic compounds were prepared in
13 methanol and stored at -20°C. All solvents used were of analytical or HPLC grade (Sigma-
14 Aldrich). Water was of Milli-Q quality (Millipore Corp, Bedford, MA).

15 **2.3. Cell Culture**

16 The human MG-63 osteosarcoma cell line was purchased from American Type Cultures
17 Collection (ATCC, Manassas, VA) and maintained in Dulbecco's Modified Eagle Medium
18 (DMEM; Invitrogen Gibco Cell Culture Products, Carlsbad, CA) with 100 IU/mL penicillin
19 (Lab Roger SA, Barcelona, Spain), 50 µg/mL gentamicin (Braun Medical SA, Jaen, Spain),
20 2.5 µg/mL amphotericin B (Sigma, St Louis, MO, USA), and 1% glutamine (Sigma, St Louis,
21 MO, USA), 2% HEPES (Sigma, St Louis, MO, USA), supplemented with 10% fetal bovine

1 serum (FBS) (Gibco, Paisley, UK). Cultures were kept at 37°C in a humidified atmosphere of
2 95% air and 5% CO₂. Cells were detached from culture flask with a solution of 0.05% trypsin
3 (Sigma, St Louis, MO, USA) and 0.02% ethylene diamine tetra-acetic acid (EDTA) (Sigma, St
4 Louis, MO, USA) and were then washed and suspended in complete culture medium with 10%
5 FBS.

6 **2.4. Antigenic phenotype by flow cytometry**

7 Osteoblasts were previously treated with 10⁻⁶M and 10⁻⁸M of apigenin, luteolin, or p-coumaric,
8 ferulic, or caffeic acid for 24 h at 37°C. Cells were then detached from the cultured flask by
9 treatment with 0.4% EDTA solution, washed and suspended in phosphate-buffered saline (PBS)
10 at 2x10⁴cells/mL. Cells were labeled by direct staining with anti-CD54, CD80, CD86, and
11 HLA-DR monoclonal antibodies (mAbs) (IOL1b, CD80, CD86, and OKDR, respectively; all
12 from Invitrogen Corp, Carlsbad, CA). The fluorochrome used to label the antibody was
13 Fluorescein-Isothiocyanate. Aliquots of 100 µl of the cell suspension were incubated with 10
14 µl of the appropriate mAb for 30 min at 4 °C in the dark. Cells were washed, suspended in 1
15 mL of PBS and immediately analyzed in a flow cytometer with diode laser (FASC Canton II,
16 SE Becton Dickinson, Palo Alto, CAL) at a wavelength of 488 nm to determine the percentage
17 of fluorescent cells. Untreated cells were stained with mAbs as negative control. The percentage
18 of antibody-positive cells was calculated from counts of 2000- 3000 cells. At least three
19 experiments were run for each antigen in all cultures.

20 **2.5. Alkaline phosphatase activity**

21 MG-63 cells were treated at confluence with culture medium containing 10mM β-
22 glycerophosphate and 50µg/mL ascorbic acid to promote differentiation. After 6 days, cells
23 were incubated with 10⁻⁶M and 10⁻⁸M of apigenin, luteolin, or p-coumaric, ferulic, or caffeic

1 acid for 48 h at 37°C in a humidified atmosphere of 95% air and 5% CO₂. Cells were lysed with
2 0.1% Triton X-100 at 37°C. The samples were centrifuged at 1500 rpm and the supernatants
3 stored at -70°C until used. ALP activity was quantified with a colorimetric assay (Diagnostic
4 kit 104-LL, Sigma, St. Louis, MO) using p-nitrophenylphosphate as substrate. An aliquot
5 (50µL) of cell lysate solution was added to 50µL of ALP substrate (Sigma) and was incubated
6 at 37°C for 45min in darkness. The enzymatic reaction was stopped by adding 50µL of 0.1M
7 NaOH, and the absorbance was measured at 405 nm with a spectrophotometer (Biotek
8 ELx800). The total protein content was estimated by the Bradford method using a protein assay
9 kit from Bio-Rad Laboratories (Nazareth-Eke, Belgium). All samples were run in triplicate, and
10 the ALP activity was expressed as a percentage, considering enzymatic activity in the absence
11 of phenolic compounds as 100%. All assays were compared to a control group of cells grown
12 under the same conditions but not treated.

13 **2.6. Statistical analysis**

14 Data were expressed as means ± standard deviation (SD) and compared using the Student's *t*-
15 test. *P* < 0.05 was considered significant in all tests. At least three experiments were performed
16 for each culture. SPSS version 20.0 (IBM, Chicago, IL) was used for all data analyses.

17 **3. RESULTS**

18 **Antigenic phenotype by flow cytometry**

19 Flow cytometry results showed a significant decrease in CD54 expression *versus* untreated
20 control cells (*p* ≤ 0.001) after treatment with each dose of each phenolic compound tested (Table
21 1). A significant decrease in CD80 expression was observed after treatment with apigenin or
22 ferulic or p-coumaric acid at doses of 10⁻⁶M (*p* = 0.006, *p* = 0.025, and *p* = 0.012, respectively) and
23 10⁻⁸M (*p* = 0.007, *p* = 0.04, and *p* = 0.007 respectively). Ferulic acid increased the expression of

1 CD86 or HLA-DR at all doses ($p < 0.001$) and caffeic acid increased CD86 expression at doses
2 of 10^{-6} and 10^{-8} M ($p < 0.001$).

3 **Effect of phenolic compound on alkaline phosphatase activity**

4 The presence in the osteogenic medium of apigenin, ferulic acid, p-coumaric acid, luteolin, and
5 caffeic acid had a positive effect ($p = 0.084$) on the ALP activity of the MG63 cells at all doses
6 except for the lowest doses of luteolin and caffeic acid (Table 2).

7

8 **4. DISCUSSION**

9 The present results demonstrate that phenolic compounds found in extra virgin olive oil exert
10 an action on various cell parameters. With regard to cell differentiation, doses of 10^{-6} M and 10^{-8}
11 M of each compound produced a major and significant increase in ALP activity, suggesting a
12 favorable effect on the maturation process. The strongest effect on ALP was obtained with
13 luteolin at higher doses.

14 It has been demonstrated that different phenolic compounds in vegetable species (e.g.,
15 resveratrol in wine or quercetin in grape or onion) can modulate osteoblastic functions, such as
16 their proliferative capacity or cell maturation, by increasing ALP activity and calcium ion
17 deposition in the extracellular matrix [16,18–20]. In that sense, previous studies have
18 demonstrated that exposure of osteoblasts to phenolic compounds in olive oil, such as,
19 hydroxytyrosol, luteolin, apigenin, p-coumaric, caffeic, and ferulic acids resulted in an increase
20 in the number of cells in 24 h. Other researches have studied different phenolic extracts which
21 stimulated MG-63 cell growth, and they induced higher cell proliferation rates than individual
22 compounds [17,21,22].

1 Osteoblast lineage differentiation is a complex process characterized by the sequential and
2 defined expression of tissue-specific genes that permit the identification of three phases:
3 proliferation, maturation, and extracellular matrix synthesis/mineralization. Specific genes for
4 the differentiated osteoblast phenotype are expressed in the second phase, including genes that
5 encode for ALP and osteocalcin, producing a high level of ALP synthesis [23].

6 With regard to the effect of polyphenols on bone cell function, it is known, for example, that
7 resveratrol can modify osteoblast function by modulating transcription factors such as
8 Cbfa1/Runx2 and bone morphogenetic proteins such as osterix and osteocalcin, all essential
9 molecules in the induction of osteoblastic differentiation that can in turn activate different genes
10 involved in these processes [16,24,25]. It has been described that the consumption of olives,
11 olive oil, and oleuropein can prevent the loss of bone mass in animal and cell models [26] . In
12 this sense, Santiago-Mora *et al* (2011) found that oleuropein, a secoiridoid polyphenol,
13 increases the expression of Runx2 and osterix, indicating that oleuropein enhances osteoblast
14 formation in both initial and later phases of differentiation. The role of oleuropein in osteoblast
15 differentiation was supported by the higher expression levels of other osteoblast markers, such
16 as ALP gene expression/activity or collagen type I gene expression after exposure to this
17 secoiridoid. In line with these findings, we have observed that other polyphenols, i.e., apigenin,
18 luteolin, and ferulic, p-coumaric and caffeic acid, which are found in olive oil, also produce a
19 significant increase in ALP synthesis, favoring osteoblastic differentiation.

20 Treatment with luteolin or apigenin or caffeic, ferulic, or p-coumaric acid produces a major
21 decrease in the expression of CD54 and CD80 antigens and modulates the expression of CD86
22 and HLA-DR. Previous studies have described that human osteoblasts obtained by primary
23 culture from bone samples showed a significantly reduced expression of CD54 and CD86 after
24 *in vitro* Transforming Growth Factor beta 1 (TGF- β 1) treatment but a significantly increased

1 expression of these co-stimulatory molecules in response to Interleukin-1 beta (IL-1 β),
2 Interferon gamma (IFN γ), or Lipopolysaccharide (LPS) [7]. In another study, osteoblastic
3 expression of Interleukin 4,12,15,18 (IL-4, IL-12, IL-15, IL-18), and IFN γ cytokines was
4 similarly modified by different growth factors (Fibroblast Growth Factor (FGF), TGF- β 1, and
5 Platelet-Derived Growth Factor (PDGF)) and cytokines (IL-1 and IFN γ) [11]. This accumulated
6 evidence led the authors to propose that the functional capacity of osteoblasts is modulated
7 during their differentiation and maturation, with a gain in their bone-forming function at the
8 expense of their immunological function [11]. Schett (2011) further corroborates this
9 hypothesis by showing that proinflammatory cytokines (such as IL-1, TNF α and IL-17) are
10 involved in bone loss. The present results also support this hypothesis, with observations of an
11 increase in ALP activity and a parallel decrease in the expression of CD54 and CD80. The
12 presence of any tested dose of ferulic or caffeic acid produced a major increase in the
13 expression of CD86 and HLA-DR, which may be associated with a state of cell activation,
14 given that their expression has been related to the degree of differentiation and/or cellular
15 activation in dendritic cells (DCs) [29]. Osteoblasts and DCs share features in common,
16 including cytokine synthesis, phagocytic capacity, antigen presentation to T lymphocytes, and
17 the expression of certain antigens, such as CD54, CD80, CD86, and HLA-DR [11,12,29]. For
18 this reason, the two cell populations have been described as antigenically, morphologically, and
19 functionally related [12]. Both the increase in ALP synthesis and the modulated expression of
20 the co-stimulatory molecules may be related to a greater synthesis of TGF- β 1 [30,31].

21 Based on the present findings, we conclude that the phenolic compounds studied induce cell
22 maturation *in vitro*, favoring formation of the extracellular matrix, as indicated by the increase
23 in ALP synthesis and loss of the expression of antigens involved in osteoblastic immune
24 functions. Further research is warranted to confirm the mechanism by which these phenolic
25 compounds favor cell maturation.

1 **ACKNOWLEDGMENTS**

2 This study was supported by the research group BIO277 (Junta de Andalucía) and
3 Department of Nursing (University of Granada). The work outlined in this article has been
4 partially funded by the Spanish Ministry of Education under FPU fellowship reference FPU15-
5 05635.

6

7 **CONFLICTS OF INTEREST**

8 The authors declare that there are no conflicts of interest.

9

10 **REFERENCES**

- 11 1. Simon LS. Osteoporosis. *Clin Geriatr Med*. 2005 Aug;21(3):603–29.
- 12 2. Suzuki A, Sekiguchi S, Asano S, Itoh M. Pharmacological topics of bone metabolism:
13 recent advances in pharmacological management of osteoporosis. *J Pharmacol Sci*. 2008
14 Apr;106(4):530–5.
- 15 3. Mundy GR. Nutritional modulators of bone remodeling during aging. *Am J Clin Nutr*.
16 2006 Feb;83(2):427S–430S.
- 17 4. Habauzit V, Horcajada M-N. Phenolic phytochemicals and bone. *Phytochem Rev*.
18 2008 Jul;7(2):313–44.
- 19 5. Notoya M, Nishimura H, Woo J-T, Nagai K, Ishihara Y, Hagiwara H. Curcumin

- 1 inhibits the proliferation and mineralization of cultured osteoblasts. *Eur J Pharmacol.* 2006
2 Mar 18;534(1-3):55-62.
- 3 6. Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis:
4 estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and
5 contributes to bone loss in aging men. *J Bone Miner Res Off J Am Soc Bone Miner Res.* 1998
6 May;13(5):763-73.
- 7 7. Perez E, Garcia-Martinez O, Arroyo-Morales M, Reyes-Botella C, Ruiz C.
8 Modulation of antigenic phenotype in cultured human osteoblast-like cells by FGFb, TGFβ1,
9 PDGF-BB, IL-2, IL-1β, LPS and IFNγ. *Biosci Rep.* 2006;26(4):281-9.
- 10 8. De Luna-Bertos E, Ramos-Torrecillas J, Garcia-Martinez O, Reyes-Botella C, Nez O, Guildford
11 A, et al. Therapeutic Doses of Nonsteroidal Anti-Inflammatory Drugs Inhibit Osteosarcoma
12 MG-63 Osteoblast-Like Cells Maturation, Viability, and Biomineralization Potential. *Sci*
13 *World J.* 2013 Sep 19;2013:e809891.
- 14 9. Díaz-Rodríguez L, García-Martínez O, Morales MA-, Rodríguez-Pérez L, Rubio-Ruiz
15 B, Ruiz C. Effects of indomethacin, nimesulide, and diclofenac on human MG-63
16 osteosarcoma cell line. *Biol Res Nurs.* 2012 Jan;14(1):98-107.
- 17 10. García-Martínez O, Reyes-Botella C, Díaz-Rodríguez L, De Luna-Bertos E, Ramos-
18 Torrecillas J, Vallecillo-Capilla MF, et al. Effect of platelet-rich plasma on growth and
19 antigenic profile of human osteoblasts and its clinical impact. *J Oral Maxillofac Surg Off J*
20 *Am Assoc Oral Maxillofac Surg.* 2012 Jul;70(7):1558-64.
- 21 11. Ruiz C, Pérez E, García-Martínez O, Díaz-Rodríguez L, Arroyo-Morales M, Reyes-
22 Botella C. Expression of cytokines IL-4, IL-12, IL-15, IL-18, and IFNγ and modulation by

- 1 different growth factors in cultured human osteoblast-like cells. *J Bone Miner Metab.* 2007
2 Sep 1;25(5):286–92.
- 3 12. Ruiz C, Pérez E, Vallecillo-Capilla M, Reyes-Botella C. Phagocytosis and allogeneic
4 T cell stimulation by cultured human osteoblast-like cells. *Cell Physiol Biochem Int J Exp*
5 *Cell Physiol Biochem Pharmacol.* 2003;13(5):309–14.
- 6 13. Rotondi A, Bendini A, Cerretani L, Mari M, Lercker G, Toschi TG. Effect of olive
7 ripening degree on the oxidative stability and organoleptic properties of cv. Nostrana di
8 Brisighella extra virgin olive oil. *J Agric Food Chem.* 2004 Jun 2;52(11):3649–54.
- 9 14. Lozano-Sánchez J, Segura-Carretero A, Menendez JA, Oliveras-Ferraros C, Cerretani
10 L, Fernández-Gutiérrez A. Prediction of extra virgin olive oil varieties through their phenolic
11 profile. Potential cytotoxic activity against human breast cancer cells. *J Agric Food Chem.*
12 2010 Sep 22;58(18):9942–55.
- 13 15. Bendini A, Cerretani L, Carrasco-Pancorbo A, Gómez-Caravaca AM, Segura-
14 Carretero A, Fernández-Gutiérrez A, et al. Phenolic molecules in virgin olive oils: a survey of
15 their sensory properties, health effects, antioxidant activity and analytical methods. An
16 overview of the last decade. *Mol Basel Switz.* 2007;12(8):1679–719.
- 17 16. Dai Z, Li Y, Quarles LD, Song T, Pan W, Zhou H, et al. Resveratrol enhances
18 proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-
19 dependent ERK1/2 activation. *Phytomedicine Int J Phytother Phytopharm.* 2007
20 Dec;14(12):806–14.
- 21 17. García-Martínez O, De Luna-Bertos E, Ramos-Torrecillas J, Ruiz C, Milia E, Lorenzo
22 ML, et al. Phenolic Compounds in Extra Virgin Olive Oil Stimulate Human Osteoblastic Cell

- 1 Proliferation. *PloS One*. 2016;11(3):e0150045.
- 2 18. Habauzit V, Horcajada M-N. Phenolic phytochemicals and bone. *Phytochem Rev*.
3 2008 Jul 1;7(2):313–44.
- 4 19. Son Y-O, Kook S-H, Choi K-C, Jang Y-S, Choi Y-S, Jeon Y-M, et al. Quercetin
5 accelerates TNF-alpha-induced apoptosis of MC3T3-E1 osteoblastic cells through caspase-
6 dependent and JNK-mediated pathways. *Eur J Pharmacol*. 2008 Jan 28;579(1–3):26–33.
- 7 20. Trzeciakiewicz A, Habauzit V, Horcajada M-N. When nutrition interacts with
8 osteoblast function: molecular mechanisms of polyphenols. *Nutr Res Rev*. 2009
9 Jun;22(1):68–81.
- 10 21. Chin K-Y, Ima-Nirwana S. Olives and Bone: A Green Osteoporosis Prevention
11 Option. *Int J Environ Res Public Health*. 2016 Jul 26;13(8):755.
- 12 22. Đudarić L, Fužinac-Smojver A, Muhvić D, Giacometti J. The role of polyphenols on
13 bone metabolism in osteoporosis. *Food Res Int*. 2015 Nov;77:290–8.
- 14 23. Papachroni KK, Karatzas DN, Papavassiliou KA, Basdra EK, Papavassiliou AG.
15 Mechanotransduction in osteoblast regulation and bone disease. *Trends Mol Med*. 2009
16 May;15(5):208–16.
- 17 24. Yamaguchi M, Jie Z. Effect of polyphenols on calcium content and alkaline
18 phosphatase activity in rat femoral tissues in vitro. *Biol Pharm Bull*. 2001 Dec;24(12):1437–
19 9.
- 20 25. Zhao J, Ohba S, Shinkai M, Chung U-I, Nagamune T. Icariin induces osteogenic
21 differentiation in vitro in a BMP- and Runx2-dependent manner. *Biochem Biophys Res*

- 1 Commun. 2008 May 2;369(2):444–8.
- 2 26. Puel C, Quintin A, Agalias A, Mathey J, Obled C, Mazur A, et al. Olive oil and its
3 main phenolic micronutrient (oleuropein) prevent inflammation-induced bone loss in the
4 ovariectomised rat. *Br J Nutr.* 2004 Jul;92(1):119–27.
- 5 27. Santiago-Mora R, Casado-Díaz A, De Castro MD, Quesada-Gómez JM. Oleuropein
6 enhances osteoblastogenesis and inhibits adipogenesis: the effect on differentiation in stem
7 cells derived from bone marrow. *Osteoporos Int J Establ Result Coop Eur Found Osteoporos*
8 *Natl Osteoporos Found USA.* 2011 Feb;22(2):675–84.
- 9 28. Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. *Eur J*
10 *Clin Invest.* 2011 Dec;41(12):1361–6.
- 11 29. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology
12 of dendritic cells. *Annu Rev Immunol.* 2000;18:767–811.
- 13 30. Gebken J, Feydt A, Brinckmann J, Notbohm H, Müller PK, Bätge B. Ligand-induced
14 downregulation of receptors for TGF-beta in human osteoblast-like cells from adult donors. *J*
15 *Endocrinol.* 1999 Jun;161(3):503–10.
- 16 31. Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, Marshall GW, et al.
17 TGF-beta regulates the mechanical properties and composition of bone matrix. *Proc Natl*
18 *Acad Sci U S A.* 2005 Dec 27;102(52):18813–8.

19

20

21

1 **TABLES**

2 **Table 1.** Expression of different antigens in MG63 cell line after 24 hours of incubation
 3 with different doses of phenolic compounds by flow cytometry.

	CD54		CD80		CD86		HLA-DR	
	Mean sd ^a	P value	Mean sd ^a	p value	Mean sd ^a	P value	Mean sd ^a	P value
Control	75.13 (4.5)	-	21.86 (2.81)	-	13.33 (0.25)	-	4.60 (0.81)	-
Luteolin 10⁻⁶ M	2.06 (0.70)	0.0001***	17.80 (3.20)	0.17	12.40 (0.45)	0.037*	5.23 (0.90)	0.42
Luteolin 10⁻⁸ M	2.36 (0.45)	0.001***	22.46 (0.76)	0.74	13.96 (0.68)	0.20	4.96 (0.60)	0.56
Apigenin 10⁻⁶M	1.60 (0.26)	0.001***	10.13 (1.96)	0.006**	14.33 (1.27)	0.25	7.60 (0.96)	0.016*
Apigenin 10⁻⁸M	0.86 (0.57)	0.001***	10.30 (1.66)	0.007**	11.50 (1.21)	0.063	5.96 (1.74)	0.31
Cafeic acid 10⁻⁶ M	3.16 (0.41)	0.001***	16.43 (1.61)	0.058	17.63 (0.90)	0.010*	5.46 (0.56)	0.21
Cafeic acid 10⁻⁸ M	3.20 (1.12)	0.001***	18.90 (1.15)	0.20	19.00 (1.64)	0.004**	5.23 (0.51)	0.33
Ferulic acid 10⁻⁶ M	0.93 (0.25)	0.001***	15.90 (0.88)	0.025*	29.13 (1.95)	0.005**	37.50 (3.67)	0.0001***
Ferulic acid 10⁻⁸ M	1.06 (0.15)	0.001***	15.60 (1.93)	0.04*	33.16 (0.72)	0.0001***	36.30 (1.21)	0.0001***
Cumaric acid 10⁻⁶M	1.76 (0.25)	0.001***	12.26 (1.62)	0.012*	13.96 (1.04)	0.40	7.00 (1.57)	0.10
Cumaric acid 10⁻⁸M	0.90 (0.10)	0.001***	7.33 (1.02)	0.007**	12.53 (0.49)	0.08	5.23 (0.11)	0.31

4 ^a standar deviation. * P < 0.05. ** P < 0.01. *** P < 0.001

5

6

1 **Table 2.** Alkaline phosphatase (ALP) activity in MG63 cell line after 48 h of treatment with
 2 different doses of phenolic compounds. Data are expressed as U/mg protein.

	% of expression	sd^a	P value
Control	100		-
Luteolin 10⁻⁶ M	209.09	8.69	0.008**
Luteolin 10⁻⁸ M	81.81	11.11	0.08
Apigenin 10⁻⁶ M	209.08	8.51	0.014*
Apigenin 10⁻⁸ M	145.45	18.75	0.05*
Cafeic acid 10⁻⁶ M	145.00	6.24	0.006**
Cafeic acid 10⁻⁸ M	127.27	7.14	0.016*
Ferulic acid 10⁻⁶ M	209.90	9.37	0.007**
Ferulic acid 10⁻⁸ M	209.09	8.69	0.015*
Cumaric acid 10⁻⁶ M	145.45	18.75	0.045*
Cumaric acid 10⁻⁸ M	100	9.09	0.68

3 ^astandar deviation, * P < 0.05, ** P < 0.01, *** P < 0.001

4